{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T06:46:39Z","timestamp":1792392399476,"version":"4.4.0"},"reference-count":42,"publisher":"Institute of Cytology and Genetics, SB RAS","issue":"6","license":[{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/vavilov.elpub.ru\/jour\/about\/editorialPolicies#openAccessPolicy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vestn. VOGiS"],"abstract":"<jats:p>\n                    Histone deacetylases (HDACs) are enzymes that provide transcriptional repression, while HDAC inhibitors are considered to be potential drugs in the treatment of Alzheimer disease (AD). Earlier we found that ceftriaxone (CEF), an antibiotic with neuroprotective activity, augmented mRNA levels of\n                    <jats:italic>Ide<\/jats:italic>\n                    and\n                    <jats:italic>Mme<\/jats:italic>\n                    , encoding enzymes involved in the catabolism of amyloid beta in the amygdala of OXYS rats, a model of sporadic AD. On the other hand, disturbances of neurotrophic factors (BDNF in particular) play an important role in AD pathogenesis. Moreover, HDACs of class I (HDAC1) are involved in the regulation of\n                    <jats:italic>Bdnf<\/jats:italic>\n                    transcriptional activity. The study was aimed to assess the effects of CEF on HDAC1 enrichment at\n                    <jats:italic>Mme<\/jats:italic>\n                    ,\n                    <jats:italic>Ide<\/jats:italic>\n                    , and\n                    <jats:italic>Bdnf<\/jats:italic>\n                    gene promoters in the amygdala of OXYS rats and on\n                    <jats:italic>Bdnf<\/jats:italic>\n                    mRNA levels in the amygdala of OXYS and Wistar rats. Chromatin immunoprecipitation and qPCR were utilized for epigenetic analysis and assay of\n                    <jats:italic>Bdnf<\/jats:italic>\n                    mRNA levels, respectively. Neither significant HDAC1 enrichment, nor its alteration under CEF treatment at the\n                    <jats:italic>Mme<\/jats:italic>\n                    or\n                    <jats:italic>Ide<\/jats:italic>\n                    promoters were found, whereas CEF attenuated HDAC1 binding at\n                    <jats:italic>Bdnf<\/jats:italic>\n                    promoter IV. This is a novel mechanism of transcription regulation by CEF in the brain, which may be involved in its neuroprotective activity. In 5-month-old OXYS rats, it seems to play a minor role, as CEF did not change\n                    <jats:italic>Bdnf<\/jats:italic>\n                    transcript 5 (containing exons IV and IX) levels. We were first to demonstrate the transcript-specific regulation of\n                    <jats:italic>Bdnf<\/jats:italic>\n                    transcription by CEF. CEF significantly increased the levels of\n                    <jats:italic>Bdnf<\/jats:italic>\n                    transcript 6 (containing exons VII, VIII, and IX). The results of our study can be taken into account in AD treatment.\n                  <\/jats:p>","DOI":"10.18699\/vjgb-26-91","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:52:28Z","timestamp":1792072348000},"page":"899-907","source":"Crossref","is-referenced-by-count":0,"title":["Epigenetic regulation of the transcriptional activity of genes mediating the neuroprotective activity of ceftriaxone in the brain in a rat model of sporadic Alzheimer disease: the involvement of histone deacetylase 1"],"prefix":"10.18699","volume":"30","author":[{"given":"A. A.","family":"Bashirzade","sequence":"first","affiliation":[{"name":"Scientific Research Institute of Neurosciences and Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"Tikhonova","sequence":"additional","affiliation":[{"name":"Scientific Research Institute of Neurosciences and Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. M.","family":"Belichenko","sequence":"additional","affiliation":[{"name":"Scientific Research Institute of Neurosciences and Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. A.","family":"Fedoseeva","sequence":"additional","affiliation":[{"name":"Scientific Research Institute of Neurosciences and Medicine"},{"name":"Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. D.","family":"Belyaev","sequence":"additional","affiliation":[{"name":"Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.-Y.","family":"Renn","sequence":"additional","affiliation":[{"name":"Taipei Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.-M.","family":"Chang","sequence":"additional","affiliation":[{"name":"Taipei Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. G.","family":"Kolosova","sequence":"additional","affiliation":[{"name":"Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. D.","family":"Belyaev","sequence":"additional","affiliation":[{"name":"Scientific Research Institute of Neurosciences and Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. G.","family":"Amstislavska","sequence":"additional","affiliation":[{"name":"Scientific Research Institute of Neurosciences and Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7950","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Alhaddad H., Alasmari F., Alhamadani B., Wong W., Bell R.L., Sari Y. Effects of chronic ethanol consumption on the expression of GLT-1 and neuroplasticity-related proteins in the nucleus accumbens of alcohol-preferring rats. Brain Res Bull. 2020;165:272-280. doi 10.1016\/j.brainresbull.2020.10.012","DOI":"10.1016\/j.brainresbull.2020.10.012"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Alsallum M., Kaminskaya Y.P., Tsybko A., Kolosova N., Naumenko V. Patterns of expression of the key genes of the BDNF system and serotonin receptors in the brain of OXYS rats in the development of the signs of Alzheimer\u2019s disease. Adv Gerontol. 2023;13(2):84-93. doi 10.1134\/S207905702360026X","DOI":"10.1134\/S207905702360026X"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Baj G., Leone E., Chao M.V., Tongiorgi E. Spatial segregation of BDNF transcripts enables BDNF to differentially shape distinct dendritic compartments. Proc Natl Acad Sci USA. 2011;108(40):16813-16818. doi 10.1073\/pnas.1014168108","DOI":"10.1073\/pnas.1014168108"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Belichenko V.M., Bashirzade A.A., Tenditnik M.V., Dubrovina N.I., Akopyan A.A., Ovsyukova M.V., Fedoseeva L.A., Pupyshev A.B., Aftanas L.I., Amstislavskaya T.G., Tikhonova M.A. Comparative analysis of early neurodegeneration signs in a mouse model of Alzheimer\u2019s disease-like pathology induced by two types of the central (Intracerebroventricular vs. Intrahippocampal) administration of A\u03b225-35 oligomers. Behav Brain Res. 2023;454:114651. doi 10.1016\/j.bbr.2023.114651","DOI":"10.1016\/j.bbr.2023.114651"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Belyaev N.D., Nalivaeva N.N., Makova N.Z., Turner A.J. Neprilysin gene expression requires binding of the amyloid precursor protein intracellular domain to its promoter: implications for Alzheimer disease. EMBO Rep. 2009;10(1):94-100. doi 10.1038\/embor.2008.222","DOI":"10.1038\/embor.2008.222"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Bondarev A.D., Attwood M.M., Jonsson J., Chubarev V.N., Tarasov V.V., Schioth H.B. Recent developments of HDAC inhibitors: Emerging indications and novel molecules. Br J Clin Pharmacol. 2021;87(12):4577-4597. doi 10.1111\/bcp.14889","DOI":"10.1111\/bcp.14889"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Cini N., Atasoy O., Uyanikgil Y., Yaprak G., Erdogan M.A., Erbas O. Ceftriaxone has a neuroprotective effect in a whole-brain irradiation-induced neurotoxicity model by increasing GLT-1 and reducing oxidative stress. Strahlenther Onkol. 2025;201(9):903-919. doi 10.1007\/s00066-025-02405-z","DOI":"10.1007\/s00066-025-02405-z"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Cudkowicz M.E., Titus S., Kearney M., Yu H., Sherman A., Schoenfeld D., Hayden D., \u2026 Simpson E., Tolkoff-Rubin N., Zinman L., Shefner J.M.; Ceftriaxone Study Investigators. Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13(11):1083-1091. doi 10.1016\/S1474-4422(14)70222-4","DOI":"10.1016\/S1474-4422(14)70222-4"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Du Y., Wu H.T., Qin X.Y., Cao C., Liu Y., Cao Z.Z., Cheng Y. Postmortem brain, cerebrospinal fluid, and blood neurotrophic factor levels in Alzheimer\u2019s disease: A systematic review and meta-analysis. J Mol Neurosci. 2018;65(3):289-300. doi 10.1007\/s12031-018-1100-8","DOI":"10.1007\/s12031-018-1100-8"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Gao R., Ali T., Liu Z., Li A., Hao L., He L., Yu X., Li S. Ceftriaxone averts neuroinflammation and relieves depressive-like behaviors via GLT-1\/TrkB signaling. Biochem Biophys Res Commun. 2024;701: 149550. doi 10.1016\/j.bbrc.2024.149550","DOI":"10.1016\/j.bbrc.2024.149550"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Ginzinger D.G. Gene quantification using real-time quantitative PCR: an emerging technology hits the mainstream. Exp Hematol. 2002; 30(6):503-512. doi 10.1016\/s0301-472x(02)00806-8","DOI":"10.1016\/S0301-472X(02)00806-8"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Hammad A.M., Swiss G.M.S., Hall F.S., Hikmat S., Sari Y., Al-Qirim T.M., Amawi H.A. Ceftriaxone reduces waterpipe tobacco smoke withdrawal-induced anxiety in rats via modulating the expression of TNF-\u03b1\/NFkB, Nrf2, and GLT-1. Neuroscience. 2021;463:128-142. doi 10.1016\/j.neuroscience.2021.03.030","DOI":"10.1016\/j.neuroscience.2021.03.030"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Hefendehl J.K., LeDue J., Ko R.W., Mahler J., Murphy T.H., MacVicar B.A. Mapping synaptic glutamate transporter dysfunction in vivo to regions surrounding A\u03b2 plaques by iGluSnFR two-photon imaging. Nat Commun. 2016;7:13441. doi 10.1038\/ncomms13441","DOI":"10.1038\/ncomms13441"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Idda M.L., Munk R., Abdelmohsen K., Gorospe M. Noncoding RNAs in Alzheimer\u2019s disease. Wiley Interdiscip Rev RNA. 2018;9(2):10. doi 10.1002\/wrna.1463","DOI":"10.1002\/wrna.1463"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Kaur B., Prakash A. Ceftriaxone attenuates glutamate-mediated neuroinflammation and restores BDNF in MPTP model of Parkinson\u2019s disease in rats. Pathophysiology. 2017;24(2):71-79. doi 10.1016\/j.pathophys.2017.02.001","DOI":"10.1016\/j.pathophys.2017.02.001"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Kumari S., Deshmukh R. \u03b2-lactam antibiotics to tame down molecular pathways of Alzheimer\u2019s disease. Eur J Pharmacol. 2021;895: 173877. doi 10.1016\/j.ejphar.2021.173877","DOI":"10.1016\/j.ejphar.2021.173877"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Kurochkin I.V., Guarnera E., Berezovsky I.N. Insulin-degrading enzyme in the fight against Alzheimer\u2019s disease. Trends Pharmacol Sci. 2018;39(1):49-58. doi 10.1016\/j.tips.2017.10.008","DOI":"10.1016\/j.tips.2017.10.008"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Lee S.G., Su Z.Z., Emdad L., Gupta P., Sarkar D., Borjabad A., Volsky D.J., Fisher P.B. Mechanism of ceftriaxone induction of excitatory amino acid transporter-2 expression and glutamate uptake in primary human astrocytes. J Biol Chem. 2008;283(19):13116-13123. doi 10.1074\/jbc.M707697200","DOI":"10.1074\/jbc.M707697200"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Nalivaeva N.N., Belyaev N.D., Turner A.J. New insights into epigenetic and pharmacological regulation of amyloid-degrading enzymes. Neurochem Res. 2016;41(3):620-630. doi 10.1007\/s11064-015-1703-1","DOI":"10.1007\/s11064-015-1703-1"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Nalivaeva N.N., Zhuravin I.A., Turner A.J. Neprilysin expression and functions in development, ageing and disease. Mech Ageing Dev. 2020;192:111363. doi 10.1016\/j.mad.2020.111363","DOI":"10.1016\/j.mad.2020.111363"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Narita M., Nunez S., Heard E., Narita M., Lin A.W., Hearn S.A., Spector D.L., Hannon G.J., Lowe S.W. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell. 2003;113(6):703-716. doi 10.1016\/s0092-8674(03)00401-x","DOI":"10.1016\/S0092-8674(03)00401-X"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Ng T.K.S., Ho C.S.H., Tam W.W.S., Kua E.H., Ho R.C. Decreased serum brain-derived neurotrophic factor (BDNF) levels in patients with Alzheimer\u2019s disease (AD): A systematic review and meta-analysis. Int J Mol Sci. 2019;20(2):257. doi 10.3390\/ijms20020257","DOI":"10.3390\/ijms20020257"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Niedzielska-Andres E., Mizera J., Sadakierska-Chudy A., Pomierny-Chamiolo L., Filip M. Changes in the glutamate biomarker expression in rats vulnerable or resistant to the rewarding effects of cocaine and their reversal by ceftriaxone. Behav Brain Res. 2019;370: 111945. doi 10.1016\/j.bbr.2019.111945","DOI":"10.1016\/j.bbr.2019.111945"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Nikolac Perkovic M., Videtic Paska A., Konjevod M., Kouter K., Svob Strac D., Nedic Erjavec G., Pivac N. Epigenetics of Alzheimer\u2019s disease. Biomolecules. 2021;11(2):195. doi 10.3390\/biom11020195","DOI":"10.3390\/biom11020195"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Palomer E., Martin-Segura A., Baliyan S., Ahmed T., Balschun D., Venero C., Martin M.G., Dotti C.G. Aging triggers a repressive chromatin state at Bdnf promoters in hippocampal neurons. Cell Rep. 2016;16(11):2889-2900. doi 10.1016\/j.celrep.2016.08.028","DOI":"10.1016\/j.celrep.2016.08.028"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Poon C.H., Tse L.S.R., Lim L.W. DNA methylation in the pathology of Alzheimer\u2019s disease: from gene to cognition. Ann N Y Acad Sci. 2020;1475(1):15-33. doi 10.1111\/nyas.14373","DOI":"10.1111\/nyas.14373"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Ramazi S., Allahverdi A., Zahiri J. Evaluation of post-translational modifications in histone proteins: A review on histone modification defects in developmental and neurological disorders. J Biosci. 2020; 45(1):135","DOI":"10.1007\/s12038-020-00099-2"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Rasero J., Alonso-Montes C., Diez I., Olabarrieta-Landa L., Remaki L., Escudero I., Mateos B., Bonifazi P., Fernandez M., Arango-Lasprilla J.C., Stramaglia S., Cortes J.M. Group-level progressive alterations in brain connectivity patterns revealed by diffusion-tensor brain networks across severity stages in Alzheimer\u2019s disease. Front Aging Neurosci. 2017;9:215. doi 10.3389\/fnagi.2017.00215","DOI":"10.3389\/fnagi.2017.00215"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Ratti E., Berry J.D., Greenblatt D.J., Loci L., Ellrodt A.S., Shefner J.M., Cudkowicz M.E. Preclinical rodent toxicity studies for long term use of ceftriaxone. Toxicol Rep. 2015;2:1396-1403. doi 10.1016\/j.toxrep.2015.09.010","DOI":"10.1016\/j.toxrep.2015.09.010"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Rudnitskaya E.A., Kolosova N.G., Stefanova N.A. Impact of changes in neurotrophic supplementation on development of Alzheimer\u2019s disease-like pathology in Oxys rats. Biochemistry (Mosc). 2017; 82(3):318-329. doi 10.1134\/S0006297917030105","DOI":"10.1134\/S0006297917030105"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Sada N., Fujita Y., Mizuta N., Ueno M., Furukawa T., Yamashita T. Inhibition of HDAC increases BDNF expression and promotes neuronal rewiring and functional recovery after brain injury. Cell Death Dis. 2020;11(8):655. doi 10.1038\/s41419-020-02897-w","DOI":"10.1038\/s41419-020-02897-w"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Schueller E., Paiva I., Blanc F., Wang X.L., Cassel J.C., Boutillier A.L., Bousiges O. Dysregulation of histone acetylation pathways in hippocampus and frontal cortex of Alzheimer\u2019s disease patients. Eur Neuropsychopharmacol. 2020;33:101-116. doi 10.1016\/j.euroneuro.2020.01.015","DOI":"10.1016\/j.euroneuro.2020.01.015"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Shvedunova M., Akhtar A. Modulation of cellular processes by histone and non-histone protein acetylation. Nat Rev Mol Cell Biol. 2022; 23(5):329-349. doi 10.1038\/s41580-021-00441-y","DOI":"10.1038\/s41580-021-00441-y"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Stefanova N.A., Kozhevnikova O.S., Vitovtov A.O., Maksimova K.Y., Logvinov S.V., Rudnitskaya E.A., Korbolina E.E., Muraleva N.A., Kolosova N.G. Senescence-accelerated OXYS rats: a model of age-related cognitive decline with relevance to abnormalities in Alzheimer disease. Cell Cycle. 2014;13(6):898-909. doi 10.4161\/cc.28255","DOI":"10.4161\/cc.28255"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Stefanova N.A., Maksimova K.Y., Kiseleva E., Rudnitskaya E.A., Muraleva N.A., Kolosova N.G. Melatonin attenuates impairments of structural hippocampal neuroplasticity in OXYS rats during active progression of Alzheimer\u2019s disease-like pathology. J Pineal Res. 2015;59(2):163-177. doi 10.1111\/jpi.12248","DOI":"10.1111\/jpi.12248"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Tikhonova M.A., Ho S.C., Akopyan A.A., Kolosova N.G., Weng J.C., Meng W.Y., Lin C.L., Amstislavskaya T.G., Ho Y.J. Neuroprotective effects of ceftriaxone treatment on cognitive and neuronal deficits in a rat model of accelerated senescence. Behav Brain Res. 2017;330: 8-16. doi 10.1016\/j.bbr.2017.05.002","DOI":"10.1016\/j.bbr.2017.05.002"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Tikhonova M.A., Amstislavskaya T.G., Belichenko V.M., Fedoseeva L.A., Kovalenko S.P., Pisareva E.E., Avdeeva A.S., Kolosova N.G., Belyaev N.D., Aftanas L.I. Modulation of the expression of genes related to the system of amyloid-beta metabolism in the brain as a novel mechanism of ceftriaxone neuroprotective properties. BMC Neurosci. 2018;19(Suppl. 1):13. doi 10.1186\/s12868-018-0412-5","DOI":"10.1186\/s12868-018-0412-5"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Tikhonova M.A., Amstislavskaya T.G., Ho Y.J., Akopyan A.A., Tenditnik M.V., Ovsyukova M.V., Bashirzade A.A., Dubrovina N.I., Aftanas L.I. Neuroprotective effects of ceftriaxone involve the reduction of A\u03b2 burden and neuroinflammatory response in a mouse model of Alzheimer\u2019s disease. Front Neurosci. 2021;15:736786. doi 10.3389\/fnins.2021.736786","DOI":"10.3389\/fnins.2021.736786"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Tran P.V., Kennedy B.C., Lien Y.C., Simmons R.A., Georgieff M.K. Fetal iron deficiency induces chromatin remodeling at the Bdnf locus in adult rat hippocampus. Am J Physiol Regul Integr Comp Physiol. 2015;308(4):R276-R282. doi 10.1152\/ajpregu.00429.2014","DOI":"10.1152\/ajpregu.00429.2014"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Zhang Y., Chen H., Li R., Sterling K., Song W. Amyloid \u03b2-based therapy for Alzheimer\u2019s disease: challenges, successes and future. Signal Transduct Target Ther. 2023;8(1):248. doi 10.1038\/s41392-023-01484-7","DOI":"10.1038\/s41392-023-01484-7"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Zuccato C., Belyaev N., Conforti P., Ooi L., Tartari M., Papadimou E., MacDonald M., Fossale E., Zeitlin S., Buckley N., Cattaneo E. Widespread disruption of repressor element-1 silencing transcription factor\/neuron-restrictive silencer factor occupancy at its target genes in Huntington\u2019s disease. J Neurosci. 2007;27(26):6972-6983. doi 10.1523\/JNEUROSCI.4278-06.2007","DOI":"10.1523\/JNEUROSCI.4278-06.2007"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Zumkehr J., Rodriguez-Ortiz C.J., Cheng D., Kieu Z., Wai T., Hawkins C., Kilian J., Lim S.L., Medeiros R., Kitazawa M. Ceftriaxone ameliorates tau pathology and cognitive decline via restoration of glial glutamate transporter in a mouse model of Alzheimer\u2019s disease. Neurobiol Aging. 2015;36(7):2260-2271. doi 10.1016\/j.neurobiolaging.2015.04.005","DOI":"10.1016\/j.neurobiolaging.2015.04.005"}],"container-title":["Vavilov Journal of Genetics and Breeding"],"original-title":[],"link":[{"URL":"https:\/\/vavilov.elpub.ru\/jour\/article\/viewFile\/5297\/2137","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T06:26:44Z","timestamp":1792391204000},"score":1,"resource":{"primary":{"URL":"https:\/\/vavilov.elpub.ru\/jour\/article\/view\/5297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":42,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,10,13]]}},"URL":"https:\/\/doi.org\/10.18699\/vjgb-26-91","relation":{},"ISSN":["2500-3259"],"issn-type":[{"value":"2500-3259","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,13]]}}}